MedTrace Logo

DNA Methylation in Malar Melasma and Its Change by Sunscreen, Retinoic Acid and Niacinamide.

NCT03392623 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2018-01-09

No results posted yet for this study

Summary

BACKGROUND: Malar melasma has a chronic and recurrent character that may be related with epigenetic changes.

Conditions

  • Melasma

Interventions

DRUG

Retinoic acid

topical administration in melasma lesions

DEVICE

colorimetry measurement

Measurement of erythema and luminosity through a colorimeter

DRUG

sunscreen

topical administration in melasma lesions

DRUG

Niacinamide

topical administration in melasma lesions

Sponsors & Collaborators

  • Universidad Autonoma de San Luis Potosí

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-01-01
Primary Completion
2016-01-01
Completion
2016-12-01
FDA Drug
Yes
FDA Device
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03392623 on ClinicalTrials.gov